I am an Independent biotechnology stock Researcher and investor based out of Dallas, Tx. My primary focus is on the small-cap biotech segment of the market. I specialize in long/short ideas as well as short-term trade strategy.
I am currently a portfolio manager at an RIA in Philadelphia with over $1 billion in assets. The portfolio is dedicated towards macro themed positioning with equities, ETFs, fixed income, as well as options and other alternatives. There are opportunities everywhere, both on the long and short side, and I aim to generate absolute returns on an annualized basis for clients. My absolute return portfolio has returned double-digit percentage returns over the last decade regardless of if the market is selling off, or rallying higher with enthusiasm. Relative returns are nice, but at the end of the day, you can't eat relative returns. When the S&P 500 is down 20%, it doesn't necessarily mean you have to be down too. Join my Marketplace service, Absolute Returns, and see how I am positioning my portfolio in real-time, and what trade ideas are coming about daily. I also offer a live chat as part of the service, where questions and ideas can be discussed.
Founded by Dr. Hung Tran, MD, MS, CNPR, (in collaboration with Dr. Tran BioSci analyst, Ngoc Vu, and other PhDs), Integrated BioSci Investing (“IBI) marketplace research is delivering robust returns since inception. To name a couple winners, Nektar Therapeutics and Spectrum Pharmaceuticals delivered profits of 446% and 196% for our subscribers, respectively. Our secret sauce is extreme due diligence coupled with expert data analysis. The service features a once-weekly exclusive in-depth Integrated BioSci article (in the form of research, reports, or interviews), daily individual stocks consulting, and model portfolios. Of note, we’ll increase our price soon (SUBSCRIBE to IBI now to lock in the current price and save money). Click the orange FOLLOW button to receive the FREE real-time alerts on our articles and blogs. To read the FREE once-weekly articles covering promising small-cap bioscience firms, check out www.drtranbiosci.com (and make sure to register for our mailing list). You can read up on Dr. Tran’s background in an in-depth article by following this link. http://www.drtranbiosci.com/p/dr-tran.html "Stellar therapeutics for patients. Differentiated intelligence for investors. Premium valuations for firms."
Former broker, now an independent analyst/writer on Seeking Alpha and founder and editor of the Growth Stock Forum. Focusing on small-cap, mid-cap and biotech stocks. Looking for substantial sales and earnings growth potential and seeking the best risk-adjusted returns from my stock selection. Taking advantage of medium to long-term momentum.
My articles represent my personal opinion and analysis and should not be regarded as investment advice in any way. Readers and subscribers should do their own due diligence and/or consult their financial advisor before making decisions to buy or sell securities. Trading and investing include risks, including loss of principal.
Exclusive research: http://seekingalpha.com/author/oneil-trader/research
I'm retired from a near 40 year career in the publishing industry working with an international publishing company. My investing experience is over a span of 40 years. Luckily with more winners than losers! My hobbies are world travel, reading good books(non-fiction)--and researching stocks that I have an interest. In my retirement, I volunteer my time working in assisting several lawyers with their Child Protective Service cases.(Drugs are destroying our Society and family structure) I also serve as a reviewer for a national literary prize given each year.
I am an investor with a background in biotechnology and genetics. My Ph.D. education and professional experience are focused on genetics, stem cells, CRISPR, next generation sequencing and gene therapy. My investments and investment ideas are focused on long plays on under-appreciated/revolutionary products at the cutting edge of science.
Full time trader and investor.
As part of my active participation in the worldwide markets I research and analyze small and mid cap stocks with a unique earnings growth opportunity. I favor growth stories over buy-and-hold value investments, typically ones with a convincing story and sales and market share growth to prove it. I also cover a long-only portfolio geared towards the younger generation's investment apatite and cover important events and breaking news on stock I cover.
I provided stock and bond research and analysis to a small cap specialist investor, Lloyd Miller, from 2002 until his death in January 2018. For my own account I invest mainly in technology and biotechnology stocks. My technology and investment web site is openicon.com, where readers can view the notes I take to make decisions and to write articles for Seeking Alpha.
EP Vantage is a forward-looking comment and analysis service tailored to the needs of pharma and finance professionals, focusing on the events that will define the future of companies, products and therapy areas. Written by experienced journalists, EP Vantage provides timely financial analysis of regulatory and patent decisions, marketing approvals, licensing deals, and M&A, giving fresh angles and insight to both current and future industry triggers. EP Vantage is powered by EvaluatePharma, the industry leader in consensus forecasts.
I am an expert in neuroscience, neurology, and genetics with M.D. and Ph.D training. I develop new therapies for genetic disorders. This as a hobby so please don’t dox me if you figure out my identity.
Long biotech: IONS, ILMN, GILD
Long tech: AAPL, FB, NVDA
Stone Fox Capital Advisors is a registered investment advisor founded in 2010. The firm offers portfolio management with a focus on opportunistic stocks providing secular growth trends at an affordable value. An emphasis is placed on fundamental analysis though charts are used for timing entry and exit points.
Mark Holder graduated from the University of Tulsa with a double major in accounting & finance. He's been interested in the stock market since college and began managing investments for friends and family more than 20 years ago. Mark has his Series 65 and is also a CPA.
Invest with Stone Fox Capital's model portfolios on Covestor.com as he makes real time trades. Covestor also allows followers to duplicate the model portfolio in their own brokerage accounts. You can find the portfolio and more details here:
Follow Mark on twitter: @stonefoxcapital
I am a Physician (Board Certified in Child Psychiatry, Adult Psychiatry, and General Pediatrics) and I have been an investor in individual biotech companies for about 5 years. I first published on Seeking Alpha in 2014 and began writing regularly in mid 2017. My focus is finding value in Biotech companies while also reviewing technical aspects of their stocks. I concentrate on Neuroscience companies and share my perspective in this area.
Welcome to the fastest growing biotechnology forum. We are a collaboration of biotechnology insights providing investment research. Currently, we are featuring our Lucky Seven swing-trading portfolio of biotechnology stocks that present with excellent short-term risk-to-reward ratios. Unlike nearly all other services, we 1. do not overwhelm you with dozens of picks to choose from; 2. give you our top three picks; 3. consider time as money too, because it is; 4. organize our picks in a manner that reflects individual risk-tolerance; 5. hold ourselves accountable for each recommendation by keeping track of all of our trades; 6. provide insight as to when to enter a ticker and when to exit (timing is everything in biotech investing). We will also occasionally present long-term ideas, research, technical analysis, etc. At the helm of Clover is Stephen Ayers. He is a Registered Nurse who works on an intermediate care unit in a hospital and witnesses first-hand the powerful impact of medicine. He is an avid biotechnology researcher and advocater. He believes collaboration with persons of differing biotechnology angles will enrich his work. Subsequently, he has formed Clover Biotech Research to provide a platform for investors to experience several different perspectives. Clover recently welcomed Gobinath Varadappan, a biomedical engineer with big pharma experience and knowledge of clinical, regulatory, and commercial aspects of drug development. Gobinath is looking forward to making vital contributions to the team. Clover plans to secure additional advisers and writers in the future.
Avisol Capital Partners runs the Total Pharma Tracker Seeking Alpha Marketplace service. This is managed by Dr Asok Dutta, BVScAH and Dr Udaya Kumar Maiya, MD Oncologist. The service offers end-to-end research on both investing and trading ideas everyday, and includes a 150-stock watchlist and two 40-stock model portfolios that are continuously tracked.
Dr Dutta is a retired veterinary surgeon. He has over 40 years experience in the industry. Dr Maiya is a well-known oncologist who has 30 years in the medical field, including as Medical Director of various healthcare institutions. Both doctors are also avid private investors. They are assisted by a number of finance professionals in developing this service.
If you want to check out our service, go here - https://seekingalpha.com/author/avisol-capital-partners/research
Disclaimer - we are not investment advisors.
The SA Investor Marketplace is where readers can subscribe to premium research and private communities from top SA authors. Marketplace services cover a wide variety of investment styles, giving readers a chance to invest alongside their favorite authors.
Interested in building a business on Marketplace? Check out this story on authors' success to date, and go here to learn more about writing for SA. Contact us at email@example.com if you'd like to apply to launch a Marketplace service.
Interested in signing up for a Marketplace service? Check out all our authors here. For any questions about SA's Marketplace, contact firstname.lastname@example.org. We'd be happy to hear from you.
This account will be used to highlight these authors and offer insights into investing from the authors to any interested users. Follow this account if you'd like to hear what's going on with the SA Marketplace!
We look for potentially undervalued stocks in biotech, technology, and commodities sectors.
We perform research, and give investment opinions and ideas to buy-side firms from time to time.
Make sure to FOLLOW and SUBSCRIBE for the most up to date publications, and access to our chat room.
We are not advisors. Please DM or e-mail email@example.com for idea generation, questions, etc.
Seeking Alpha's product team is responsible for the development of all of our product-related projects from start to finish. These projects include the Seeking Alpha Portfolio apps on the App Store and Google Play, our Real Time email alert product, and optimization across the Seeking Alpha website.
The purpose of this profile is to allow us to share with our readers all new product developments. Please follow us on Seeking Alpha to receive updates. We look forward to your input and feedback!
SA Product Team
I am a biotech investor with a PhD in Biochemistry and Molecular Biology. I hope to provide a crucial piece of total due diligence as well as interesting insight into clinical findings that may impact readers' portfolios and lives.
I also collaborate with Avisol Capital Partners on their Marketplace service known as the Total Pharma Tracker (TPT). Some of my work will be available to TPT subscribers either exclusively, or in advance. If you are interested, please click the link above!
Investor/Trader in biotech and tech sectors for 10 years. Founder & Editor of ROTY (Runners of the Year), a strategy and now Marketplace Service focused on discovering opportunities to achieve high % gains within a year´s time frame.
Importantly, I often highlight risk management and entry/exit strategies, as I believe they represent areas that are often neglected but materially important for readers to understand and apply if they want to be profitable long term.
I am the Founder of Biotech Analysis Central, A subscription service on Seeking Alpha's Marketplace. If you want to learn more about biotech investing or you want to check out my biotech analysis you can do so with a free 2-week trial to my service. Just hit the "Learn More" button on the bottom of the Marketplace Research Tab. I have a Bachelors of Applied Science Degree In Technology Management, Industrial and Business Services Management from St. Petersburg College Florida. I have been investing in biotech stocks for many years, and I prefer to invest as a long term investor. With that In mind I seek stocks that have long term value! I primarily Like to Invest In biotechnology stocks and I accept the risks. I Write for the Healthcare Sector and Stock market in general. I contribute to Seeking Alpha, Talk Markets, and CNA Finance. I run my own biotechnology website Biotechpicklist.com
You can follow me on stocktwits.com under the name BiopharmaPro where I currently have (60,043) followers. Join me in my quest to find the best biotechnology stocks that deliver results to help patients with new treatment options. I am not afraid to find some biotech stocks to short either after results have proven a drug to be ineffective. Looking at both the negative and positive aspects of biotech investing is the best way to invest in this sector.
SA PRO author & marketplace contributor. Successful PRO calls include $AKAO (+400% within 6 months) & $MRNS (+450% within 6 months).
I am providing members of my marketplace service, 'Second-Level Investing' with exclusive ideas, analysis and interviews with managers and subject matter experts.
- A former diplomat & entrepreneur. A former Project Manager at UN Principles for Responsible Investment
- An alumni of SciencesPo Paris
- Based in Luxembourg
RagingBull.com is the premier destination for both new or experienced active traders who are looking for stock picks, stock ideas, how to get started trading stocks, and overall stock market education. Our team is comprised of real millionaire stock traders who put their money to work every day in the markets by actively trading penny stocks, ETF’s, options, small-cap stocks and biotech stocks.
The Busted IPO Forum founded by Bret Jensen, is a hypothetical $150K portfolio built of stocks that have been public for 18 months to five years that are significantly under their offering price. Many times after the initial analyst hyperbole has died and lockups have expired, these same companies can be had for .30 to .50 cents on the dollar from when the shares went public. As lucrative as this niche has been for Bret's portfolio over the years, a service or newsletter has not existed that covered this segment of the market -- until now! The goal in creating the Busted IPO Forum is to build a portfolio of 15-20 small cap and mid cap busted IPOs which consistently outperform the Russell 2000 over time.
• • •
Specializing in profiling high beta sectors, Bret Jensen founded and also manages The Biotech Forum, The Insiders Forum, and the Busted IPO Forum model portfolios. Finding “gems” in the biotech and small-cap stock sectors, these highly volatile spaces proven hugely successful have empowered Bret Jensen's own investing portfolio.
• • •
Learn more about Bret Jensen's Marketplace offerings:
The Insiders Forum | The Biotech Forum | Busted IPO Forum
Stephen Simpson, CFA, is a freelance financial writer and investor.
I have worked for both sell-side and buy-side firms (equities and fixed income), with the largest percentage of my working time spent in med-tech. At this point I am now effectively in a "working retirement".
I write because I find that the process helps me take better notes, be more disciplined about modeling, and come up with a more coherent investment view for my portfolio management needs. If I'm writing about a stock, it's generally because I'm interested in it as an investment prospect or I think there's an interesting story to tell.
I don't share my models, so please don't ask.
More of my writings can be found at my blog Kratisto Investing (kratistoinvesting.blogspot.com), or Twitter (@Kratisto_Invest).
MBBS, MD, MBA (NYU-Stern, Finance): worked/did research at Cornell and Harvard Affiliated Hospitals
Portfolio Manager/founder for own US biotech/pharma-focused asset management firm, Vasuda Capital Management (vasudacapitalmanagement.com).
Founder/Editor: Vasuda Healthcare Analytics: SA Marketplace premium biotech/pharma research service
Founder and Sponsor: Vasuda Global Orphan/Rare Diseases Index, first global equity index representing the orphan/rare disease sector (vasudaindices.com), index calculator=Solactive A.G. https://www.vasudaindices.com